Can Teva Win With The Big Pharma Playbook?

ByShankar N:2012 has been a do-nothing year for Teva Pharmaceuticals TEVA. Its stock is still at the same place where it started the year and the 2010 peak of $64 seems like Mount Everest. The stock is trading at a forward P/E of 6.9 and it's definitely worth investigating. The Company

By Stephen Simpson:While the seemingly endless M&A process among generic drug companies means that the acquisition of Par Pharmaceuticals (PRX) isn't a complete surprise, it's an interesting deal all the same. Not only does this deal point to the cost of not having a truly global business, but it also seems to speak to the extent to which this sector could see pipeline-driven valuation worries in the coming years.

By Bret Jensen:Generic drug makers (And those with a combination of branded and generic products) have some of their lowest valuations in a decade by a variety of metrics (P/E, P/S). Given some of the strong secular trends such as an aging population in the West, constraints on government budgets and numerous blockbuster branded pharmaceuticals coming off patent over the next few years; this provides a long term buying opportunity.

The Burrill Report submits: Teva Pharmaceutical (TEVA) will pay about $5 billion for Germany's second largest generic drugs maker, Ratiopharm, beating out Pfizer's (PFE) bid and maintaining its rank as the world's top generics company by sales. Novartis (NVS) remains the world's second-biggest generics maker.

By Doolan Wesley:In an ever-evolving world of healthcare and medicine, society is always looking for advanced treatments to address their needs.

By Stock Croc:As in the case of other major pharmaceutical companies, Sanofi (SNY) faces increasing competition from 'generics' (copycats of the company's blockbuster products after expiry of patent protection).

By Mark Bern, CPA CFA Teva Pharmaceuticals (TEVA) is one of the largest manufacturers and marketers of generic drugs in the world, and has a proprietary drug development, manufacturing and marketing effort with a global reach as well. While the dividend is lower than other companies in the drug sector, there is a good reason that it should provide investors greater return over the long-term.

Think Yield submits:With health care reform growing in political popularity, there will be an increase in demand for drugs, especially cheaper, generic ones. Teva’s (TEVA) undisputed dominance of the generic drug market assures profitability and earning growth in the future.